(P111) Insulin Efsitora Alfa Phase 3 Type 2 Diabetes Trial Results Overview

Once-weekly insulin efsitora alfa (efsitora) completed a Phase 3 development program, which included four trials in adults with type 2 diabetes. This poster highlights the results of the trials, which demonstrated comparable efficacy and safety between Efsitora and daily basal insulins. Efsitora showed a noninferior reduction in HbA1c and similar rates of combined clinically significant or severe hypoglycemia and percent time in glucose range (70-180 mg/dL) versus daily basal insulins.